Cargando…

The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes

BACKGROUND: To determine whether 12 months of intensive medical therapy (IMT) improves HDL functionality parameters in subjects with type II diabetes (T2D). METHODS: Retrospective, randomized, and controlled 12-month IMT intervention trial that enrolled 13-subjects with T2D (age 51- years, fasting g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kashyap, Sangeeta, Kheniser, Karim, Li, Ling, Bena, James, Kasumov, Takhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002094/ https://www.ncbi.nlm.nih.gov/pubmed/27567897 http://dx.doi.org/10.1186/s12944-016-0314-4

Ejemplares similares

Erratum to: The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
por: Kashyap, Sangeeta, et al.
Publicado: (2016)

Temporal Dynamics of High-Density Lipoprotein Proteome in Diet-Controlled Subjects with Type 2 Diabetes
por: Kheniser, Karim G., et al.
Publicado: (2020)

A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function
por: Kheniser, K. G., et al.
Publicado: (2019)

Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2023)

Plasma Ceramides Are Elevated in Obese Subjects With Type 2 Diabetes and Correlate With the Severity of Insulin Resistance
por: Haus, Jacob M., et al.
Publicado: (2009)

Double‐blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study
por: Kashyap, Sangeeta R., et al.
Publicado: (2020)

Duration of Type 2 Diabetes and Very Low Density Lipoprotein Levels Are Associated with Cognitive Dysfunction in Metabolic Syndrome
por: Yogi-Morren, Divya, et al.
Publicado: (2014)

High Density Lipoprotein and it’s Dysfunction
por: Eren, Esin, et al.
Publicado: (2012)

High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes
por: Androulakis, Emmanuel, et al.
Publicado: (2017)

Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications
por: Bonilha, Isabella, et al.
Publicado: (2021)

High-Density Lipoprotein Function and Dysfunction in Health and Disease
por: Chiesa, Scott T., et al.
Publicado: (2019)

Turnover of histones and histone variants in postnatal rat brain: effects of alcohol exposure
por: Rachdaoui, Nadia, et al.
Publicado: (2017)

Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics
por: Salazar, Juan, et al.
Publicado: (2015)

Anticipatory Role of High Density Lipoprotein and Endothelial Dysfunction: An Overview
por: Eren, Esin, et al.
Publicado: (2014)

Dysfunctional high-density lipoprotein in chronic inflammatory rheumatic diseases
por: Waldecker-Gall, Sabina, et al.
Publicado: (2023)

Nintedanib ameliorates oxidized low-density lipoprotein -induced inflammation and cellular senescence in vascular endothelial cells
por: Li, Ling, et al.
Publicado: (2022)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Trypanosome Lytic Factor, an Antimicrobial High-Density Lipoprotein, Ameliorates Leishmania Infection
por: Samanovic, Marie, et al.
Publicado: (2009)

Circadian Rhythm of Subspecies of Low-Density Lipoprotein-Cholesterol and High-Density Lipoprotein-Cholesterol in Healthy Subjects and Patients with Type 2 Diabetes
por: Hayashi, Toshiyuki, et al.
Publicado: (2023)

High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential
por: Jomard, Anne, et al.
Publicado: (2020)

Favorable therapeutic efficacy of low‐density lipoprotein apheresis for nephrotic syndrome with impaired renal function
por: Muso, Eri, et al.
Publicado: (2021)

Early Pro-Inflammatory Remodeling of HDL Proteome in a Model of Diet-Induced Obesity: (2)H(2)O-Metabolic Labeling-Based Kinetic Approach
por: Sadana, Prabodh, et al.
Publicado: (2020)

Hepatic paraoxonase 1 ameliorates dysfunctional high-density lipoprotein and atherosclerosis in scavenger receptor class B type I deficient mice
por: Zhao, Xiao-Jie, et al.
Publicado: (2021)

Dysfunctional high-density lipoprotein: not only quantity but first of all quality?
por: Agouridis, Aris P., et al.
Publicado: (2015)

Low-density lipoprotein modified by myeloperoxidase oxidants induces endothelial dysfunction
por: Abdo, Adrian I., et al.
Publicado: (2017)

Oxidized Low-Density Lipoprotein Drives Dysfunction of the Liver Lymphatic System
por: Burchill, Matthew A., et al.
Publicado: (2020)

High-density lipoprotein ameliorates palmitic acid-induced lipotoxicity and oxidative dysfunction in H9c2 cardiomyoblast cells via ROS suppression
por: Wu, Kuen-Ming, et al.
Publicado: (2019)

Triglyceride to high-density lipoprotein cholesterol ratio and total cholesterol to high-density lipoprotein cholesterol ratio and risk of benign prostatic hyperplasia in Chinese male subjects
por: Zhu, Chen, et al.
Publicado: (2022)

Association between measured or calculated small dense low‐density lipoprotein cholesterol and oxidized low‐density lipoprotein in subjects with or without type 2 diabetes mellitus
por: Kim, Hyun‐Ki, et al.
Publicado: (2022)

Anti-High-Density Lipoprotein Antibodies and Antioxidant Dysfunction in Immune-Driven Diseases
por: Rodríguez-Carrio, Javier, et al.
Publicado: (2018)

Characteristics of High-density Lipoprotein Subclasses Distribution for Subjects with Desirable Total Cholesterol Levels
por: Tian, Li, et al.
Publicado: (2011)

Identification of Glycoxidative Lesion in Isolated Low-Density Lipoproteins from Diabetes Mellitus Subjects
por: Alyahyawi, Amjad R., et al.
Publicado: (2023)

High Density Lipoprotein: A Therapeutic Target in Type 2 Diabetes
por: Barter, Philip J.
Publicado: (2013)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Efficacy of low- and moderate-intensity statins for achieving low- density lipoprotein cholesterol targets in Thai type 2 diabetic patients
por: Thongtang, Nuntakorn, et al.
Publicado: (2017)

Patients with Rheumatoid Arthritis Show Altered Lipoprotein Profiles with Dysfunctional High-Density Lipoproteins that Can Exacerbate Inflammatory and Atherogenic Process
por: Kim, Jae-Yong, et al.
Publicado: (2016)

Functionally Defective High-Density Lipoprotein and Paraoxonase: A Couple for Endothelial Dysfunction in Atherosclerosis
por: Eren, Esin, et al.
Publicado: (2013)

Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients
por: Rysz-Górzyńska, Magdalena, et al.
Publicado: (2016)

Electronegative very-low-density lipoprotein induces brain inflammation and cognitive dysfunction in mice
por: Lin, Ying-Shao, et al.
Publicado: (2021)

Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
por: Abdalwahab, Ahmed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nf9akqe8pn775hval6a4p70e8t